Federal
Bring Entrepreneurial Advancements To Consumers Here In North America Act
Source: Congress.gov ·
1,515 words in original text
Plain English summary not yet available
The full original text is available below. Check back soon as we process this bill.
II
116TH CONGRESS
2D SESSION
S. 3945
To amend the Internal Revenue Code of 1986 to provide incentives for
relocating manufacturing of pharmaceuticals and medical supplies and
devices to the United States.
IN THE SENATE OF THE UNITED STATES
JUNE 11, 2020
Mrs. LOEFFLER (for herself, Ms. ERNST, and Mr. CRUZ) introduced the
following bill; which was read twice and referred to the Committee on Finance
A BILL
To amend the Internal Revenue Code of 1986 to provide
incentives for relocating manufacturing of pharma-
ceuticals and medical supplies and devices to the United
States.
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled,
2
SECTION 1. SHORT TITLE.
3
This Act may be cited as the ‘‘Bring Entrepreneurial
4
Advancements To Consumers Here In North America
5
Act’’.
6
SEC. 2. FINDINGS.
7
Congress finds as follows:
8
VerDate Sep 11 2014
07:21 Jun 26, 2020
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\S3945.IS
S3945
pbinns on DSKJLVW7X2PROD with BILLS
2
•S 3945 IS
(1) In late December 2019, authorities in the
1
city of Wuhan in China’s Hubei Province reported a
2
cluster of pneumonia cases of unknown cause.
3
(2) The Government of the People’s Republic of
4
China eventually identified the cause of the outbreak
5
to be a novel coronavirus that would later be under-
6
stood to cause a respiratory illness in humans,
7
known as COVID–19.
8
(3) The pandemic spread of COVID–19 and the
9
geographic location of its origin caused reverbera-
10
tions in medical supply chains that reached around
11
the world.
12
(4) The COVID–19 pandemic highlights the
13
United States dependency on China for critical med-
14
ical supplies and pharmaceutical products.
15
(5) The Government of the People’s Republic of
16
China and the Chinese Communist Party prioritize
17
state support for biotechnology manufacturing as a
18
strategic industry under the ‘‘Made in China 2025’’
19
initiative.
20
(6) According to the United States Food and
21
Drug Administration, as of 2018, China is the larg-
22
est exporter of medical devices and the second larg-
23
est exporter of drugs and biologics to the United
24
States.
25
VerDate Sep 11 2014
07:21 Jun 26, 2020
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\S3945.IS
S3945
pbinns on DSKJLVW7X2PROD with BILLS
3
•S 3945 IS
(7) Chinese pharmaceutical companies produce
1
more than 90 percent of the supply of antibiotics, vi-
2
tamin C, ibuprofen, and hydrocortisone in the
3
United States.
4
(8) In March 2020, Xinhua News Service, a
5
Chinese state-controlled news agency, reprinted an
6
article insinuating that if China were to announce
7
its ‘‘strategic control’’ of medical products and ban
8
exports to the United States, ‘‘the United States
9
would be plunged into the vast ocean of novel
10
coronavirus.’’
11
(9) The ability of the Government of the Peo-
12
ple’s Republic of China and the Chinese Communist
13
Party to control the medical supply chain poses a
14
risk to the national security of the United States.
15
(10) Companies should be incentivized through
16
a competitive tax structure to manufacture and
17
produce pharmaceuticals and medical devices in the
18
United States.
19
SEC. 3. TAX INCENTIVES FOR RELOCATING MANUFAC-
20
TURING OF PHARMACEUTICALS AND MED-
21
ICAL
SUPPLIES
AND
DEVICES
TO
THE
22
UNITED STATES.
23
(a) ACCELERATED DEPRECIATION
FOR NONRESI-
24
DENTIAL REAL PROPERTY.—Section 168 of the Internal
25
VerDate Sep 11 2014
07:21 Jun 26, 2020
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\S3945.IS
S3945
pbinns on DSKJLVW7X2PROD with BILLS
4
•S 3945 IS
Revenue Code of 1986 is amended by adding at the end
1
the following new subsection:
2
‘‘(n) ACCELERATED DEPRECIATION FOR NONRESI-
3
DENTIAL REAL PROPERTY ACQUIRED IN CONNECTION
4
WITH THE RELOCATION OF MANUFACTURING OF PHAR-
5
MACEUTICALS AND MEDICAL SUPPLIES AND DEVICES TO
6
THE UNITED STATES.—
7
‘‘(1) TREATMENT AS 20-YEAR PROPERTY.—For
8
purposes of this section, qualified nonresidential real
9
property shall be treated as 20-year property.
10
‘‘(2) APPLICATION OF BONUS DEPRECIATION.—
11
For application of bonus depreciation to qualified
12
nonresidential real property, see subsection (k).
13
‘‘(3) QUALIFIED NONRESIDENTIAL REAL PROP-
14
ERTY.—For purposes of this subsection, the term
15
‘qualified nonresidential real property’ means non-
16
residential real property placed in service in the
17
United States by a qualified manufacturer if such
18
property is acquired by such qualified manufacturer
19
in connection with a qualified relocation of manufac-
20
turing.
21
‘‘(4) QUALIFIED
MANUFACTURER.—For pur-
22
poses of this subsection, the term ‘qualified manu-
23
facturer’ means any person engaged in the trade or
24
VerDate Sep 11 2014
07:21 Jun 26, 2020
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\S3945.IS
S3945
pbinns on DSKJLVW7X2PROD with BILLS
5
•S 3945 IS
business of manufacturing a qualified medical prod-
1
uct.
2
‘‘(5) QUALIFIED MEDICAL PRODUCT.—For pur-
3
poses of this subsection, the term ‘qualified medical
4
product’ means any pharmaceutical, medical device,
5
or medical supply.
6
‘‘(6) QUALIFIED
RELOCATION
OF
MANUFAC-
7
TURING.—For purposes of this subsection—
8
‘‘(A) IN
GENERAL.—The term ‘qualified
9
relocation of manufacturing’ means, with re-
10
spect to any qualified manufacturer, the reloca-
11
tion of the manufacturing of a qualified medical
12
product from a foreign country to the United
13
States.
14
‘‘(B) RELOCATION OF PROPERTY NOT RE-
15
QUIRED.—For purposes of subparagraph (A),
16
manufacturing shall not fail to be treated as re-
17
located merely because property used in such
18
manufacturing was not relocated.
19
‘‘(C) RELOCATION
OF
NOT
LESS
THAN
20
EQUIVALENT
PRODUCTIVE
CAPACITY
RE-
21
QUIRED.—For purposes of subparagraph (A),
22
manufacturing shall not be treated as relocated
23
unless the property manufactured in the United
24
States is substantially identical to the property
25
VerDate Sep 11 2014
07:21 Jun 26, 2020
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\S3945.IS
S3945
pbinns on DSKJLVW7X2PROD with BILLS
6
•S 3945 IS
previously manufactured in a foreign country
1
and the increase in the units of production of
2
such property in the United States by the quali-
3
fied manufacturer is not less than the reduction
4
in the units of production of such property in
5
such foreign country by such qualified manufac-
6
turer.
7
‘‘(7) APPLICATION
TO
POSSESSIONS
OF
THE
8
UNITED STATES.—For purposes of this subsection,
9
the term ‘United States’ includes any possession of
10
the United States.’’.
11
(b) EXCLUSION OF GAIN ON DISPOSITION OF PROP-
12
ERTY IN CONNECTION WITH QUALIFIED RELOCATION OF
13
MANUFACTURING.—
14
(1) IN GENERAL.—Part III of subchapter B of
15
chapter 1 of such Code is amended by inserting
16
after section 139H the following new section:
17
‘‘SEC. 139I. EXCLUSION OF GAIN ON DISPOSITION OF PROP-
18
ERTY IN CONNECTION WITH QUALIFIED RE-
19
LOCATION OF MANUFACTURING.
20
‘‘(a) IN GENERAL.—In the case of a qualified manu-
21
facturer, gross income shall not include gain from the sale
22
or exchange of qualified relocation disposition property.
23
‘‘(b) QUALIFIED RELOCATION DISPOSITION PROP-
24
ERTY.—For purposes of this section, the term ‘qualified
25
VerDate Sep 11 2014
07:21 Jun 26, 2020
Jkt 099200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\S3945.IS
S3945
pbinns on DSKJLVW7X2PROD with BILLS
7
•S 3945 IS
relocation disposition property’ means any property
1
which—
2
‘‘(1) is sold or exchanged by a qualified manu-
3
facturer in connection with a qualified relocation of
4
manufacturing, and
5
‘‘(2) was used by such qualified manufacturer
6
in the trade or business of manufacturing a qualified
7
medical product in the foreign country from which
8
such manufacturing is being relocated.
9
‘‘(c) OTHER TERMS.—Terms used in this section
10
which are also used in subsection (n) of section 168 shall
11
have the same meaning when used in this section as when
12
used in such subsection.’’.
13
(2) CLERICAL AMENDMENT.—The table of sec-
14
tions for part III of subchapter B of chapter 1 of
15
such Code is amended by inserting after the item re-
16
lating to section 139H the following new item:
17
‘‘Sec. 139I. Exclusion of gain on disposition of property in connection with
qualified relocation of manufacturing.’’.
(c) EFFECTIVE DATES.—
18
(1)
ACCELERATED
DEPRECIATION.—The
19
amendment made by subsection (a) shall apply to
20
property placed in service after the date of the en-
21
actment of this Act.
22
VerDate Sep 11 2014
07:21 Jun 26, 2020
Jkt 099200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\S3945.IS
S3945
pbinns on DSKJLVW7X2PROD with BILLS
8
•S 3945 IS
(2) EXCLUSION
OF
GAIN.—The amendments
1
made by subsection (b) shall apply to sales and ex-
2
changes after the date of the enactment of this Act.
3
Æ
VerDate Sep 11 2014
07:21 Jun 26, 2020
Jkt 099200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6301
E:\BILLS\S3945.IS
S3945
pbinns on DSKJLVW7X2PROD with BILLS
Important: This plain English summary was generated by AI and is provided for informational purposes only.
It is not legal advice. Always consult the official bill text on Congress.gov
or a qualified attorney for legal matters.